Printer Friendly

ADA, EASD Issue New Recommendations for T2DM; Additional focus on lifestyle management, self-management education and support emphasized.

WEDNESDAY, Oct. 10, 2018 (HealthDay News) -- Recommendations for the management of type 2 diabetes have been updated, according to a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published online Oct. 5 in Diabetes Care.

Melanie J. Davies, M.D., from the University of Leicester in the United Kingdom, and colleagues updated previous position statements on the management of type 2 diabetes in adults, with the goals of treatment being preventing or delaying complications and maintaining quality of life.

The recommendations include additional focus on lifestyle management and diabetes self-management education and support. Efforts targeting weight loss, including lifestyle, medication, and surgical interventions, are recommended for those with obesity. A sodium-glucose cotransporter 2 (SGLT2) inhibitor or glucagon-like peptide 1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended for patients with clinical cardiovascular disease. An SGLT2 inhibitor with proven benefit is recommended for patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease. The first injectable medication recommended is a GLP-1 receptor agonist.

"We are proud to call for this paradigm shift as the most logical and appropriate next steps in care through this joint consensus report with EASD," William T. Cefalu, M.D., chief scientific, medical, and mission officer for the ADA, said in a statement. "The needs of our patients require that we consider the many individual life factors in order to improve quality and length of life for as many people as possible."

Several authors disclosed financial ties to pharmaceutical and medical device companies.

Abstract/Full Text

COPYRIGHT 2018 HealthDay
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Physician's Briefings
Date:Oct 10, 2018
Words:263
Previous Article:Prevalence of Anxiety, Depression Up for Adults With Arthritis; Age-standardized prevalences of anxiety, depression symptoms 22.5 and 12.1 percent...
Next Article:Accepted Manuscripts Meet More Criteria for Research Reporting; Certain items, such as objectives, translation of risk poorly reported in most...
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters